Fulcrum Shares Surge 60% on Upcoming Sickle Cell and Muscular Dystrophy Data
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Fulcrum Therapeutics Inc (NASDAQ: FULC, Korean name: 풀크럼 테라퓨틱스) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. As of December 8, 2025, its shares traded at $14.31, reflecting an increase of 60.79% on a trading volume of 1,340,911 on the NASDAQ exchange. The company utilizes proprietary technologies to identify and modulate gene targets for genetically defined rare diseases.
Corporate Structure
Founded in 2016, Fulcrum employs between 51 and 200 people, according to its LinkedIn profile. The team includes professionals with expertise in gene regulation, neuromuscular disorders, rare genetic diseases, and cardiovascular diseases. Key leadership includes CEO Alex Sapir, and as of late 2025, Lisa Percival has taken on the role of Chief Regulatory Officer.
Gene therapy by Sangharsh Lohakare
Recent Developments and News
On August 29, 2025, Fulcrum’s online pipeline presentation outlined programs for Diamond Blackfan Anemia (DBA) and Bone Marrow Failure Syndromes (BMFS). Key assets include:
- FTX-6058 (pociredir): an oral small molecule designed to induce fetal hemoglobin (HbF) in patients with sickle cell disease. The Phase 1b PIONEER study (NCT05169580) is ongoing, with topline safety and pharmacodynamic readouts expected in the first half of 2026.
- Losmapimod: advanced into Phase 2 for facioscapulohumeral muscular dystrophy, aiming for disease-modifying outcomes via p38 MAP kinase inhibition.
In November 2025, Fulcrum participated with over 60 rare-disease companies in urging Congress to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program, signing a joint CEO letter to emphasize the importance of maintaining incentives for pediatric therapy development.
Financial and Strategic Analysis
As of intraday trading on December 8, 2025, Fulcrum’s valuation and key metrics were:
| Metric | Value |
|---|---|
| Share Price | $14.31 |
| Market Cap (intraday) | $600.17 M |
| Enterprise Value | $404.92 M |
| TTM EPS | –1.14 |
| Total Cash (mrq) | $200.64 M |
| Debt/Equity (mrq) | 3.53% |
| Price/Sales (ttm) | 5.46 |
| Price/Book (mrq) | 3.02 |
| Beta (5Y Monthly) | 3.18 |
| Return on Assets (ttm) | –20.63% |
| Return on Equity (ttm) | –31.21% |
| Net Income (ttm) | –$71.11 M |
| Levered Free Cash Flow (ttm) | –$36.09 M |
Fulcrum has not yet generated product revenue. Its cash position and moderate leverage indicate operational viability into mid-2026, considering ongoing expenditures related to clinical programs.
Market Position and Industry Context
Fulcrum operates within the clinical-stage rare-disease sector, competing against other biopharmaceutical firms involved in the development of small-molecule and gene-modulation therapies. The PRV incentive program has been instrumental in attracting investment to this field. Fulcrum’s beta (3.18) suggests a heightened sensitivity to developments within the sector and trial outcomes. Its focus on genetically defined targets places it among specialists addressing disease mechanisms rather than just symptomatic treatment.
tl;dr
On December 8, 2025, Fulcrum shares increased by 60.79% to $14.31 with notable trading volume. Drivers include anticipated Phase 1b PIONEER data for FTX-6058 in sickle cell disease due in the first half of 2026, ongoing Phase 2 results for losmapimod, and legislative efforts for the reauthorization of the Rare Pediatric Disease PRV Program. Cash reserves of $200.64 million support operations through mid-2026 based on current expenditure rates.